Your browser doesn't support javascript.
loading
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos, Meletios A; Oriol, Albert; Nahi, Hareth; San-Miguel, Jesus; Bahlis, Nizar J; Usmani, Saad Z; Rabin, Neil; Orlowski, Robert Z; Suzuki, Kenshi; Plesner, Torben; Yoon, Sung-Soo; Ben Yehuda, Dina; Richardson, Paul G; Goldschmidt, Hartmut; Reece, Donna; Ahmadi, Tahamtan; Qin, Xiang; Garvin Mayo, Wendy; Gai, Xue; Carey, Jodi; Carson, Robin; Moreau, Philippe.
Afiliación
  • Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Nahi H; Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
  • San-Miguel J; Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
  • Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
  • Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Rabin N; Department of Haematology, University College London Hospitals NHS Trust, London, United Kingdom.
  • Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Plesner T; Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
  • Yoon SS; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Ben Yehuda D; Hematology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
  • Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Goldschmidt H; GMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany.
  • Reece D; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
  • Ahmadi T; Genmab US Inc, Plainsboro, NJ.
  • Qin X; Janssen Research & Development, LLC, Spring House, PA.
  • Garvin Mayo W; Janssen Research & Development, LLC, Raritan, NJ.
  • Gai X; Janssen Research & Development, LLC, Beijing, China.
  • Carey J; Janssen Research & Development, LLC, Spring House, PA.
  • Carson R; Janssen Research & Development, LLC, Spring House, PA.
  • Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France.
J Clin Oncol ; 41(8): 1590-1599, 2023 03 10.
Article en En | MEDLINE | ID: mdl-36599114
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Estados Unidos